Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Circassia Pharmaceuticals ( (GB:NIOX) ) has issued an update.
NIOX Group plc has applied to the London Stock Exchange for a block admission of 165,413 new ordinary shares of 0.08 pence each to be admitted to trading on AIM. The shares will be issued from time to time upon the exercise of options under the company’s 2023 Save As You Earn Plan and, once admitted, will rank pari passu with NIOX’s existing ordinary share capital, modestly expanding the company’s equity base to accommodate employee share participation.
The most recent analyst rating on (GB:NIOX) stock is a Hold with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company’s robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc is a UK-listed company whose shares trade on AIM, the London Stock Exchange’s market for smaller, growth-oriented companies.
Average Trading Volume: 954,594
Technical Sentiment Signal: Buy
Current Market Cap: £286.7M
See more data about NIOX stock on TipRanks’ Stock Analysis page.